Cargando…
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML). However, similar to T-cells expressing chimeric antigen receptors (CARs), their antitumor activity is li...
Autores principales: | Mu-Mosley, Hong, Ostermann, Lauren, Muftuoglu, Muharrem, Vaidya, Abishek, Bonifant, Challice L., Velasquez, Mireya Paulina, Gottschalk, Stephen, Andreeff, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124830/ https://www.ncbi.nlm.nih.gov/pubmed/35615350 http://dx.doi.org/10.3389/fimmu.2022.880108 |
Ejemplares similares
-
Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015) -
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
por: Riberdy, Janice M., et al.
Publicado: (2020) -
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
por: Vaidya, Abishek, et al.
Publicado: (2022) -
CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014) -
Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)